Fate Therapeutics (NASDAQ:FATE – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Fate Therapeutics to related companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, risk, dividends and profitability.
Earnings & Valuation
This table compares Fate Therapeutics and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fate Therapeutics | $6.65 million | -$136.32 million | -1.96 |
| Fate Therapeutics Competitors | $735.81 million | $13.62 million | -10.07 |
Fate Therapeutics’ peers have higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Fate Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -65.08% | -41.73% |
| Fate Therapeutics Competitors | -9,054.47% | -198.89% | -30.64% |
Volatility & Risk
Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Fate Therapeutics’ peers have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.
Insider & Institutional Ownership
97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations for Fate Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Fate Therapeutics Competitors | 9782 | 15050 | 45286 | 1571 | 2.54 |
Fate Therapeutics presently has a consensus price target of $5.90, indicating a potential upside of 187.10%. As a group, “Biotechnology” companies have a potential upside of 96.62%. Given Fate Therapeutics’ higher probable upside, equities analysts plainly believe Fate Therapeutics is more favorable than its peers.
Summary
Fate Therapeutics peers beat Fate Therapeutics on 7 of the 13 factors compared.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
